T-Cell Therapy: Options for Infectious Diseases
The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61Suppl 3 |
|---|---|
| Enthalten in: |
Clinical infectious diseases - 61Suppl 3(2015), 8, Seite S217-S224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parida, Shreemanta K [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| doi: |
10.1093/cid/civ615 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956632840 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956632840 | ||
| 003 | DE-627 | ||
| 005 | 20230714141615.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/civ615 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956632840 | ||
| 035 | |a (DE-599)GBVOLC1956632840 | ||
| 035 | |a (PRQ)g2125-480cbff5ba9e5d9958a65081c56b998de29b8e1f676ab68a5fb6671b855a06130 | ||
| 035 | |a (KEY)0124598820150000061000800217tcelltherapyoptionsforinfectiousdiseases | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 100 | 1 | |a Parida, Shreemanta K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-Cell Therapy: Options for Infectious Diseases |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy. | ||
| 540 | |a Nutzungsrecht: © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. | ||
| 540 | |a © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. 2015 | ||
| 650 | 4 | |a Care and treatment | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 4 | |a Research | |
| 650 | 4 | |a Cellular therapy | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a Disease prevention | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a T cell receptors | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Mtb | |
| 650 | 4 | |a Advances in Tuberculosis Research | |
| 650 | 4 | |a T-cells | |
| 650 | 4 | |a A Blueprint for Opportunities | |
| 650 | 4 | |a host-directed therapy | |
| 650 | 4 | |a CAR | |
| 650 | 4 | |a adoptive cell therapy | |
| 700 | 1 | |a Poiret, Thomas |4 oth | |
| 700 | 1 | |a Zhenjiang, Liu |4 oth | |
| 700 | 1 | |a Meng, Qingda |4 oth | |
| 700 | 1 | |a Heyckendorf, Jan |4 oth | |
| 700 | 1 | |a Lange, Christoph |4 oth | |
| 700 | 1 | |a Ambati, Aditya S |4 oth | |
| 700 | 1 | |a Rao, Martin V |4 oth | |
| 700 | 1 | |a Valentini, Davide |4 oth | |
| 700 | 1 | |a Ferrara, Giovanni |4 oth | |
| 700 | 1 | |a Rangelova, Elena |4 oth | |
| 700 | 1 | |a Dodoo, Ernest |4 oth | |
| 700 | 1 | |a Zumla, Alimuddin |4 oth | |
| 700 | 1 | |a Maeurer, Markus |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases |d Cary, NC : Oxford Univ. Press, 1992 |g 61Suppl 3(2015), 8, Seite S217-S224 |w (DE-627)131041878 |w (DE-600)1099781-7 |w (DE-576)028046099 |x 1058-4838 |7 nnns |
| 773 | 1 | 8 | |g volume:61Suppl 3 |g year:2015 |g number:8 |g pages:S217-S224 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1093/cid/civ615 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26409284 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1718994066 |
| 856 | 4 | 2 | |u http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4583575&tool=pmcentrez&rendertype=abstract |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 61Suppl 3 |j 2015 |e 8 |h S217-S224 | ||